Title:
PHARMACEUTICAL COMPOSITION COMPRISING KAI1 POLYPEPTIDE FOR INHIBITION OF HEPATIC FIBROSIS AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/033534
Kind Code:
A1
Abstract:
The KAI1 protein or a fragment thereof according to the present invention inhibited hepatic fibrosis in mice in which acute hepatic fibrosis was induced by CCl4. The KAI1 protein suppressed hepatic fibrosis by inhibiting fibrosis of hepatocytes treated with TGF-β1 and promoting senescence of hepatic stellate cells. Therefore, the pharmaceutical composition comprising the KAI1 protein according to the present invention can be used to effectively prevent or treat hepatic fibrosis.
More Like This:
Inventors:
HUR JIN (KR)
HAN JUNG-HWA (KR)
LEE SOO YONG (KR)
HAN JUNG-HWA (KR)
LEE SOO YONG (KR)
Application Number:
PCT/KR2022/013013
Publication Date:
March 09, 2023
Filing Date:
August 31, 2022
Export Citation:
Assignee:
NAT UNIV PUSAN IND UNIV COOP FOUND (KR)
International Classes:
A61K38/17; A61K38/10; A61P1/16; A61P43/00
Domestic Patent References:
| WO2018092137A1 | 2018-05-24 |
Foreign References:
| KR20160131258A | 2016-11-16 | |||
| KR20160131259A | 2016-11-16 | |||
| US6204000B1 | 2001-03-20 |
Other References:
ZHANG WU, ZHAO CHENG-GUANG, SUN HONG-YU, ZHENG WEI-E, CHEN HUA: "Expression Characteristics of KAI1 and Vascular Endothelial Growth Factor and Their Diagnostic Value for Hepatocellular Carcinoma", GUT AND LIVER, GUT AND LIVER, EDITORIAL OFFICE, KR, vol. 8, no. 5, 15 September 2014 (2014-09-15), KR , pages 536 - 542, XP093042288, ISSN: 1976-2283, DOI: 10.5009/gnl13331
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF: